Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 1,076 Shares of Stock

by · The Cerbat Gem

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) Director Nina S. Kjellson sold 1,076 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $17.01, for a total transaction of $18,302.76. Following the completion of the transaction, the director now directly owns 458,390 shares in the company, valued at $7,797,213.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tyra Biosciences Stock Up 2.1 %

TYRA traded up $0.36 on Wednesday, hitting $17.12. 604,045 shares of the company traded hands, compared to its average volume of 189,731. The company has a 50 day moving average of $22.18 and a 200-day moving average of $19.98. Tyra Biosciences, Inc. has a 12-month low of $10.60 and a 12-month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, research analysts anticipate that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Trading of Tyra Biosciences

Institutional investors have recently modified their holdings of the business. Oppenheimer & Co. Inc. purchased a new stake in shares of Tyra Biosciences during the 1st quarter worth $977,000. Vanguard Group Inc. lifted its stake in shares of Tyra Biosciences by 18.6% in the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after purchasing an additional 140,833 shares during the period. American Century Companies Inc. boosted its holdings in Tyra Biosciences by 582.9% during the second quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after buying an additional 145,346 shares in the last quarter. Perceptive Advisors LLC grew its position in Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares during the period. Finally, Ensign Peak Advisors Inc acquired a new position in Tyra Biosciences during the second quarter worth about $3,047,000. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Piper Sandler began coverage on Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target on the stock. Oppenheimer increased their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Finally, HC Wainwright raised their target price on shares of Tyra Biosciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Buy” and an average target price of $31.40.

Read Our Latest Report on Tyra Biosciences

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Recommended Stories